busulfan has been researched along with Malignant Melanoma in 29 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chemotherapy-naive patients with proven metastatic uveal melanoma were randomly assigned to receive 1000 mg/m(2) of gemcitabine plus 3500 mg/m(2) of treosulfan (GeT) or 3500 mg/m(2) of T." | 9.12 | A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. ( Bechrakis, NE; Foerster, MH; Keilholz, U; Martus, P; Schmidt-Hieber, M; Schmittel, A; Schuster, R; Siehl, JM; Thiel, E, 2006) |
| "To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma." | 9.12 | Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2007) |
| "This trial was performed to define the maximum tolerated dose (MTD) of treosulfan administered in combination with a fixed dose of gemcitabine in uveal melanoma patients." | 9.11 | A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours. ( Bechrakis, N; Foerster, MH; Keilholz, U; Schmittel, A; Schuster, R; Siehl, J; Thiel, E, 2004) |
| "Gemcitabine plus treosulfan (GeT) is under investigation in metastatic uveal melanoma." | 9.11 | Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. ( Baumgart, J; Bechrakis, NE; Bornfeld, N; Foerster, MH; Keilholz, U; Scheulen, ME; Schmittel, A; Strumberg, D; Thiel, E, 2005) |
| "The purpose of this multicentre phase II trial was to evaluate time to progression, survival time, rate of objective tumour response and toxicity of second-line intravenous treosulfan chemotherapy in stage IV melanoma patients." | 9.10 | Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. ( Baumgart, J; Deutschmann, A; Hauschild, A; Mohr, P; Neuber, K; Pföhler, C; Pichlmeier, U; Reinhold, U, 2003) |
| "The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced melanoma patients." | 9.10 | Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. ( Gille, J; Kaufmann, R; Spieth, K, 2003) |
| "We compared the efficacy and tolerability of cisplatin, gemcitabine, and treosulfan (CGT) therapy in younger patients (age, <60 years) and in elderly patients (age, ≥60 years) with pretreated relapsed American Joint Committee on Cancer stage IV cutaneous malignant melanoma." | 7.77 | Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2011) |
| "The efficacy of cisplatin, gemcitabine, and treosulfan (CGT) was evaluated in patients with chemotherapy pretreated relapsed AJCC stage IV uveal malignant melanoma." | 7.74 | Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2008) |
| " A case of malignant melanoma of the glans penis in a chronic myeloid leukemia (CML) Ph'-positive patient after 13 years on busulfan treatment is described." | 7.67 | Malignant melanoma of the glans penis in a chronic myeloid leukemia patient after busulfan therapy. ( Manna, A; Muretto, P; Palazzi, M; Pazzaglia, C; Porcellini, A; Sparaventi, G, 1987) |
| "Uveal melanoma is relatively uncommon accounting for fewer than 5% of all melanoma cases." | 6.72 | A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma. ( Butt, M; Eswar, CV; Gillis, P; Marshall, E; O'Neill, PA, 2006) |
| "Paclitaxel was also active, particularly in combination with treosulfan (47%) or mitoxantrone (33%)." | 5.30 | Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. ( Cree, IA; Foss, AJ; Hungerford, JL; Kurbacher, CM; Myatt, N; Neale, MH; Plowman, PN, 1999) |
| "Chemotherapy-naive patients with proven metastatic uveal melanoma were randomly assigned to receive 1000 mg/m(2) of gemcitabine plus 3500 mg/m(2) of treosulfan (GeT) or 3500 mg/m(2) of T." | 5.12 | A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. ( Bechrakis, NE; Foerster, MH; Keilholz, U; Martus, P; Schmidt-Hieber, M; Schmittel, A; Schuster, R; Siehl, JM; Thiel, E, 2006) |
| "To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma." | 5.12 | Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2007) |
| "Results from in vitro chemosensitivity testing recommend treosulfan/gemcitabine chemotherapy for the treatment of stage IV uveal melanoma." | 5.11 | Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. ( Becker, JC; Bröcker, EB; Terheyden, P, 2004) |
| "This trial was performed to define the maximum tolerated dose (MTD) of treosulfan administered in combination with a fixed dose of gemcitabine in uveal melanoma patients." | 5.11 | A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours. ( Bechrakis, N; Foerster, MH; Keilholz, U; Schmittel, A; Schuster, R; Siehl, J; Thiel, E, 2004) |
| "Gemcitabine plus treosulfan (GeT) is under investigation in metastatic uveal melanoma." | 5.11 | Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. ( Baumgart, J; Bechrakis, NE; Bornfeld, N; Foerster, MH; Keilholz, U; Scheulen, ME; Schmittel, A; Strumberg, D; Thiel, E, 2005) |
| "The purpose of this multicentre phase II trial was to evaluate time to progression, survival time, rate of objective tumour response and toxicity of second-line intravenous treosulfan chemotherapy in stage IV melanoma patients." | 5.10 | Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. ( Baumgart, J; Deutschmann, A; Hauschild, A; Mohr, P; Neuber, K; Pföhler, C; Pichlmeier, U; Reinhold, U, 2003) |
| "The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced melanoma patients." | 5.10 | Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. ( Gille, J; Kaufmann, R; Spieth, K, 2003) |
| "30) versus busulfan-based myeloablative regimens; were diagnosed with acute graft-versus-host disease (GVHD) with stage 2+ skin involvement (OR = 1." | 3.96 | Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. ( Battiwalla, M; Brazauskas, R; Buchbinder, D; Cahoon, EK; Curtis, RE; Engels, EA; Flowers, ME; Herr, MM; Morton, LM; Shaw, BE; Tecca, HR; Tucker, MA, 2020) |
| "We compared the efficacy and tolerability of cisplatin, gemcitabine, and treosulfan (CGT) therapy in younger patients (age, <60 years) and in elderly patients (age, ≥60 years) with pretreated relapsed American Joint Committee on Cancer stage IV cutaneous malignant melanoma." | 3.77 | Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2011) |
| "The efficacy of cisplatin, gemcitabine, and treosulfan (CGT) was evaluated in patients with chemotherapy pretreated relapsed AJCC stage IV uveal malignant melanoma." | 3.74 | Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2008) |
| "In this study we have used a standardised ATP-based tumour chemosensitivity assay (ATP-TCA) to measure the activity of gefitinib alone or in combination with different cytotoxic drugs (cisplatin, gemcitabine, oxaliplatin and treosulfan) against a variety of solid tumours (n = 86), including breast, colorectal, oesophageal and ovarian cancer, carcinoma of unknown primary site, cutaneous and uveal melanoma, non-small cell lung cancer (NSCLC) and sarcoma." | 3.72 | The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. ( Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P, 2004) |
| " A case of malignant melanoma of the glans penis in a chronic myeloid leukemia (CML) Ph'-positive patient after 13 years on busulfan treatment is described." | 3.67 | Malignant melanoma of the glans penis in a chronic myeloid leukemia patient after busulfan therapy. ( Manna, A; Muretto, P; Palazzi, M; Pazzaglia, C; Porcellini, A; Sparaventi, G, 1987) |
| "Treatment with Busulfan plus Fludarabine depleted lymphocytes only weakly." | 2.75 | Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. ( Appay, V; Canellini, G; Laurent, J; Leyvraz, S; Papaioannou, A; Rimoldi, D; Romero, P; Rufer, N; Speiser, DE; Touvrey, C; Vicari, M; Voelter, V, 2010) |
| "Uveal melanoma is relatively uncommon accounting for fewer than 5% of all melanoma cases." | 2.72 | A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma. ( Butt, M; Eswar, CV; Gillis, P; Marshall, E; O'Neill, PA, 2006) |
| "Paclitaxel was also active, particularly in combination with treosulfan (47%) or mitoxantrone (33%)." | 1.30 | Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. ( Cree, IA; Foss, AJ; Hungerford, JL; Kurbacher, CM; Myatt, N; Neale, MH; Plowman, PN, 1999) |
| " The dose-response relationships between BUS and SCEs in vitro were found to be similar for bone marrow and lymphocytes." | 1.26 | Spontaneous and busulphan-induced sister-chromatid exchange (SCE) frequencies in haematologically normal human bone marrow and lymphocytes. ( Honeycombe, JR, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (20.69) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 17 (58.62) | 29.6817 |
| 2010's | 2 (6.90) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Herr, MM | 1 |
| Curtis, RE | 1 |
| Tucker, MA | 1 |
| Tecca, HR | 1 |
| Engels, EA | 1 |
| Cahoon, EK | 1 |
| Battiwalla, M | 1 |
| Buchbinder, D | 1 |
| Flowers, ME | 1 |
| Brazauskas, R | 1 |
| Shaw, BE | 1 |
| Morton, LM | 1 |
| Saakyan, SV | 1 |
| Tsygankov, АY | 1 |
| Moiseeva, NI | 1 |
| Karamysheva, АF | 1 |
| Garri, DD | 1 |
| Atzpodien, J | 3 |
| Terfloth, K | 3 |
| Fluck, M | 3 |
| Reitz, M | 3 |
| Laurent, J | 1 |
| Speiser, DE | 1 |
| Appay, V | 1 |
| Touvrey, C | 1 |
| Vicari, M | 1 |
| Papaioannou, A | 1 |
| Canellini, G | 1 |
| Rimoldi, D | 1 |
| Rufer, N | 1 |
| Romero, P | 1 |
| Leyvraz, S | 1 |
| Voelter, V | 1 |
| Neuber, K | 5 |
| Reinhold, U | 4 |
| Deutschmann, A | 1 |
| Pföhler, C | 3 |
| Mohr, P | 1 |
| Pichlmeier, U | 1 |
| Baumgart, J | 2 |
| Hauschild, A | 2 |
| Cree, IA | 5 |
| Ugurel, S | 2 |
| Kuwert, C | 1 |
| Haass, N | 1 |
| Hengge, U | 1 |
| Corrie, PG | 2 |
| Zutt, M | 1 |
| Tilgen, W | 2 |
| Spieth, K | 2 |
| Kaufmann, R | 1 |
| Gille, J | 1 |
| PRESNOV, MA | 1 |
| Terheyden, P | 1 |
| Bröcker, EB | 1 |
| Becker, JC | 1 |
| Keilholz, U | 4 |
| Schuster, R | 3 |
| Schmittel, A | 4 |
| Bechrakis, N | 1 |
| Siehl, J | 1 |
| Foerster, MH | 4 |
| Thiel, E | 4 |
| Knight, LA | 1 |
| Di Nicolantonio, F | 1 |
| Whitehouse, P | 1 |
| Mercer, S | 1 |
| Sharma, S | 1 |
| Glaysher, S | 1 |
| Johnson, P | 1 |
| Neale, MH | 2 |
| Kurbacher, CM | 2 |
| Shaw, J | 1 |
| Spanswick, VJ | 1 |
| Sehmbi, R | 1 |
| Jonson, A | 1 |
| Mayer, A | 1 |
| Bulusu, R | 1 |
| Hartley, JA | 1 |
| Scheulen, ME | 1 |
| Bechrakis, NE | 3 |
| Strumberg, D | 1 |
| Bornfeld, N | 1 |
| Siehl, JM | 2 |
| Mauch, C | 1 |
| O'Neill, PA | 1 |
| Butt, M | 1 |
| Eswar, CV | 1 |
| Gillis, P | 1 |
| Marshall, E | 1 |
| Schmidt-Hieber, M | 1 |
| Martus, P | 1 |
| Schadendorf, D | 1 |
| Thoelke, A | 1 |
| Ulrich, J | 1 |
| Kaatz, M | 1 |
| Rittgen, W | 1 |
| Delorme, S | 1 |
| Honeycombe, JR | 1 |
| Myatt, N | 1 |
| Foss, AJ | 1 |
| Hungerford, JL | 1 |
| Plowman, PN | 1 |
| tom Dieck, A | 1 |
| Blödorn-Schlicht, N | 1 |
| Itschert, G | 1 |
| Karnbach, C | 1 |
| Peters, WP | 1 |
| Henner, WD | 1 |
| Grochow, LB | 1 |
| Olsen, G | 1 |
| Edwards, S | 1 |
| Stanbuck, H | 1 |
| Stuart, A | 1 |
| Gockerman, J | 1 |
| Moore, J | 1 |
| Bast, RC | 1 |
| Millar, JL | 1 |
| McElwain, TJ | 1 |
| Sparaventi, G | 1 |
| Manna, A | 1 |
| Muretto, P | 1 |
| Pazzaglia, C | 1 |
| Palazzi, M | 1 |
| Porcellini, A | 1 |
| Ishikawa, M | 1 |
| Koga, Y | 1 |
| Hosokawa, M | 1 |
| Kobayashi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma[NCT00779714] | Phase 3 | 360 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 trials available for busulfan and Malignant Melanoma
| Article | Year |
|---|---|
Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.
Topics: Aged; Busulfan; Cancer Vaccines; CD8 Antigens; Cell Proliferation; Cyclophosphamide; Cytokines; Fema | 2010 |
Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; B | 2003 |
Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Busulfan; Disease Progression; Fe | 2003 |
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 2003 |
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Cell Division; Cell Survival; C | 2003 |
Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols | 2004 |
A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Female; Gemcit | 2004 |
Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comet Assay; Deoxycytidine; D | 2005 |
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas | 2005 |
A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Deoxycytidine | 2005 |
A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Dacarbazine; Female; Humans; | 2006 |
A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytid | 2006 |
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Busulfan | 2006 |
Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan | 2007 |
Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Busulfan; | 1999 |
14 other studies available for busulfan and Malignant Melanoma
| Article | Year |
|---|---|
Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Busulfan; Case-Control Studies; Child; Child, Preschool; Femal | 2020 |
Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo.
Topics: Adult; Aged; Antineoplastic Agents; Benzeneacetamides; Busulfan; Cell Proliferation; Cell Survival; | 2020 |
Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2011 |
HISTOLOGICAL AND HISTOCHEMICAL DATA ON THE PROCESS OF REGRESSION OF EXPERIMENTAL TUMOURS INDUCED BY ALKYLATING AGENTS.
Topics: Alkaline Phosphatase; Alkylating Agents; Animals; Antineoplastic Agents; Aziridines; Busulfan; Carci | 1964 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2004 |
Treosulfan and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Gemcitabine; Humans; Melano | 2005 |
[Metronomic chemotherapy. Should we change our thinking in the treatment of advanced tumors?].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Human | 2005 |
Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Fem | 2008 |
Spontaneous and busulphan-induced sister-chromatid exchange (SCE) frequencies in haematologically normal human bone marrow and lymphocytes.
Topics: Adult; Aged; Bone Marrow; Breast Neoplasms; Busulfan; Carcinoma; Cells, Cultured; Chromosomes; Cross | 1981 |
Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; | 1999 |
Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors.
Topics: Adult; Bone Marrow; Busulfan; Carcinoma, Hepatocellular; Drug Evaluation; Female; Humans; Liver Neop | 1987 |
The concept of priming.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfa | 1985 |
Malignant melanoma of the glans penis in a chronic myeloid leukemia patient after busulfan therapy.
Topics: Busulfan; Humans; Leukemia, Myeloid; Male; Melanoma; Middle Aged; Penile Neoplasms | 1987 |
Augmentation of B16 melanoma lung colony formation in C57BL/6 mice having marked granulocytosis.
Topics: Animals; Busulfan; Female; Fibrosarcoma; Leukocyte Count; Leukocytosis; Lung Neoplasms; Melanoma; Mi | 1986 |